Abstract
This is an update to the EtR framework for the following policy question:
Should individuals ages 5–11 years receive a Pfizer-BioNTech COVID-19 vaccine booster dose at least 5 months after completion of the primary series, based on the balance of benefits and risks?
Presented during the meeting of May 19th 2022.
- Background paper
- Americas
- United States of America
- children
- COVID-19